BDABF Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables From Installed BaseBoule’s business model generates recurring revenue via consumables and service after instrument placements. An installed base creates predictable, high-frequency consumable demand that supports steady revenue streams and margins over multiple years, enhancing cash flow durability.
Stable Gross MarginsCore product economics show consistent low-to-mid 40% gross margins, indicating durable unit-level profitability. Stable gross margins provide a buffer for operating leverage and support margin sustainability if top-line volumes recover or cost control continues.
Turnaround To Positive Operating And Free Cash FlowTrailing‑12‑month operating and free cash flow have returned to positive, improving liquidity and reducing near-term refinancing pressure. Positive FCF underpins investment in service, consumables scale, and R&D, making the business more resilient despite past volatility.
Bears Say
Rising LeverageDebt rising above equity materially weakens the balance sheet and reduces financial flexibility. Higher leverage increases interest and refinancing risk, limits ability to invest in growth or weather cyclical revenue weakness, and amplifies downside if earnings remain uneven.
Top-line DeclineRevenue declines undermine operating leverage and the recurring consumables model’s potential scale benefits. Sustained top-line weakness can compress margins, reduce installed-base growth, and make cash flow improvements harder to sustain over the medium term.
Persistent Small Net LossesDespite operating profit, the company posts small net losses, indicating non-operating costs or interest burdens offsetting core results. Continued bottom-line losses impede equity rebuild, limit capital allocation flexibility, and leave results vulnerable to margin or demand shocks.
Boule Diagnostics AB News
BDABF FAQ
What was Boule Diagnostics AB’s price range in the past 12 months?
Currently, no data Available
What is Boule Diagnostics AB’s market cap?
Boule Diagnostics AB’s market cap is $14.58M.
When is Boule Diagnostics AB’s upcoming earnings report date?
Boule Diagnostics AB’s upcoming earnings report date is Oct 23, 2026 which is in 89 days.
How were Boule Diagnostics AB’s earnings last quarter?
Boule Diagnostics AB released its earnings results on Jul 17, 2026. The company reported $0.001 earnings per share for the quarter, the consensus estimate of $0.001 by $0.
Is Boule Diagnostics AB overvalued?
According to Wall Street analysts Boule Diagnostics AB’s price is currently Undervalued.
Does Boule Diagnostics AB pay dividends?
Boule Diagnostics AB does not currently pay dividends.
What is Boule Diagnostics AB’s EPS estimate?
Boule Diagnostics AB’s EPS estimate is >-0.01.
How many shares outstanding does Boule Diagnostics AB have?
Boule Diagnostics AB has 38,833,103 shares outstanding.
What happened to Boule Diagnostics AB’s price movement after its last earnings report?
Boule Diagnostics AB reported an EPS of $0.001 in its last earnings report, expectations of $0.001. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Boule Diagnostics AB?
Currently, no hedge funds are holding shares in BDABF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.